Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Interview · May 22, 2018

PARP Inhibitors and Carboplatin for Neoadjuvant Triple Negative Breast Cancer Treatment—A West Cancer Center Perspective

Lee Schwartzberg MD, FACP
Erin Schenk MD, PhD
Interview questions written by
Erin Schenk MD, PhD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Lee Schwartzberg MD, FACP

Further Reading

Most Watched This Week

Related Videos